Monte Rosa Therapeutics, Inc. (GLUE) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
321 HARRISON AVENUE BOSTON, MA 02118 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 224,254 | 128,101 | 54,912 | 346,071 | |||
| Cash and cash equivalent | 224,254 | 128,101 | 54,912 | 346,071 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | |||||||
| Restricted cash and investments | 960 | ||||||
| Other undisclosed current assets | 153,186 | 108,111 | 220,014 | 2,595 | |||
| Total current assets: | 377,440 | 236,212 | 275,886 | 348,666 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 26,831 | 28,808 | 34,832 | ||||
| Property, plant and equipment | 29,483 | 33,803 | 27,075 | 12,325 | |||
| Restricted cash and investments | 4,863 | 4,580 | 4,318 | 5,338 | |||
| Other noncurrent assets | 115 | 352 | 278 | ||||
| Total noncurrent assets: | 61,292 | 67,543 | 66,503 | 17,663 | |||
| TOTAL ASSETS: | 438,732 | 303,755 | 342,389 | 366,329 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 25,435 | 18,745 | 13,486 | 10,861 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 4,303 | ||
| Accounts payable | 17,215 | 11,152 | 7,862 | 6,558 | |||
| Accrued liabilities | 8,220 | 7,593 | 5,624 | ||||
| Deferred revenue | 117,232 | 17,678 | |||||
| Other liabilities | 3,354 | 1,671 | 5,020 | 840 | |||
| Other undisclosed current liabilities | 10,925 | 8,498 | 7,063 | 4,937 | |||
| Total current liabilities: | 156,946 | 46,592 | 25,569 | 16,638 | |||
| Noncurrent Liabilities | |||||||
| Liabilities, other than long-term debt | 42,703 | 45,590 | 45,407 | 2,176 | |||
| Liability, pension and other postretirement and postemployment benefits | 3,702 | 2,713 | 1,533 | 2,176 | |||
| Operating lease, liability | 39,001 | 42,877 | 43,874 | ||||
| Other undisclosed noncurrent liabilities | 16,147 | 32,323 | |||||
| Total noncurrent liabilities: | 58,850 | 77,913 | 45,407 | 2,176 | |||
| Total liabilities: | 215,796 | 124,505 | 70,976 | 18,814 | |||
| Temporary equity, including noncontrolling interest | 347,515 | ||||||
| Equity | |||||||
| Equity, attributable to parent | 222,936 | 179,250 | 271,413 | 347,515 | |||
| Common stock | 6 | 5 | 5 | 5 | |||
| Additional paid in capital | 664,874 | 547,857 | 503,696 | 471,566 | |||
| Accumulated other comprehensive loss | (3,356) | (2,724) | (1,752) | (2,021) | |||
| Accumulated deficit | (438,588) | (365,888) | (230,536) | (122,035) | |||
| Other undisclosed equity | (347,515) | ||||||
| Total equity: | 222,936 | 179,250 | 271,413 | ||||
| TOTAL LIABILITIES AND EQUITY: | 438,732 | 303,755 | 342,389 | 366,329 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|---|
| Revenues | 75,622 | |||||
| Gross profit: | 75,622 | |||||
| Operating expenses | (156,734) | (143,311) | (112,384) | (72,882) | ||
| Operating income (loss): | (81,112) | (143,311) | (112,384) | (72,882) | ||
| Nonoperating income (expense) | 10,982 | 8,297 | 3,883 | (1,076) | ||
| Gain (loss), foreign currency transaction, before tax | 416 | (930) | 10 | (162) | ||
| Interest and debt expense | (198) | (19) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (70,130) | (135,212) | (108,520) | (73,958) | ||
| Other undisclosed income from continuing operations before income taxes | 198 | |||||
| Income (loss) from continuing operations before income taxes: | (70,130) | (135,014) | (108,520) | (73,958) | ||
| Income tax expense | (2,570) | (338) | ||||
| Income (loss) from continuing operations: | (72,700) | (135,352) | (108,520) | (73,958) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (73,958) | |
| Other undisclosed net income | 19 | |||||
| Net income (loss) available to common stockholders, diluted: | (72,700) | (135,352) | (108,501) | (73,958) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (72,700) | (135,352) | (108,501) | (73,958) | ||
| Other comprehensive income (loss) | 600 | 1,000 | 300 | (1,000) | ||
| Other undisclosed comprehensive income | ||||||
| Comprehensive income (loss): | (72,100) | (134,352) | (108,201) | (74,958) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (1,232) | (1,972) | (31) | 35 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (73,332) | (136,324) | (108,232) | (74,923) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.